Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: jef saunders who wrote (8207)	12/10/2001 2:36:08 PM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

OT Look who ANP hired for IR. Check out his bio. Someone like Avelar would be a good fit for DMX, no? Angiotech appoints Avelar as VP of investor relations Angiotech Pharmaceuticals Inc ANP Shares issued 15,383,356 Dec 7 close $82.00 Mon 10 Dec 2001 News Release Mr. William Hunter reports Dr. Rui Avelar, MD, CCFP, DIP Sport Med, has joined the company as vice-president, investor relations and communications. At Angiotech, Dr. Avelar will be responsible for showcasing the company before the world's investment community, promoting current and developing products to the financial sector. He will also provide advice and counsel regarding integrated investor, public and media relations strategies. Dr. Avelar brings a wealth of experience to Angiotech Pharmaceuticals. Prior to accepting this position, he was a biotechnology analyst and venture capital technical analyst for Haywood Securities in Vancouver, B.C. He is also an active lecturer for continuing medical education as well as team physician for the Vancouver Canucks hockey organization. "Rui's addition as an investor relations professional will strengthen relationships with the investment community," said William L. Hunter, MD, MSc, Angiotech's chairman and chief executive officer. "Rui has followed our company's growth as an analyst for some time and brings a wealth of medical and financial experience that will assist our shareholders. I can think of no one more qualified or talented to manage the maintenance, growth and expansion of such a dynamic part of our business." Dr. Avelar received his doctorate of medicine from the University of Toronto as well as his undergraduate studies in microbiology, biochemistry and cell biology. Prior to Haywood Securities, he maintained a successful, private sports medicine practice. He is a member of the College of Physicians and Surgeons of British Columbia and Academy of Sports Medicine. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 2001 Canjex Publishing Ltd. stockwatch.com